Abstracts

Dendritic Cell-Based HIV Therapeutic Vaccine Increases Residual Viremia in Individuals on ART

Background: We evaluated the impact of therapeutic vaccination with an autologous dendritic cell (DC) vaccine pulsed with autologous, inactivated HIV-1-infected apoptotic cells on the level of residual plasma viremia in individuals on suppressive antiretroviral therapy (ART) and following analytic treatment interruption (ATI). Methodology: Autologous HIV-1 was obtained from 10 ART-naive subjects prior to starting ART.…

HIV-1 Rebound Following Allogeneic Stem Cell Transplantation and Treatment Interruption

Background: We reported the loss of detectable HIV-1 reservoirs in 2 individuals following reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (HSCT) from CCR5 wild-type donors. HIV-1 remained undetectable from blood and rectal tissue on ART despite the testing of large numbers of PBMCs or CD4+ T cells in the setting of full donor chimerism. As…

Home Antenatal Clinic or VCT: Preferences of Pregnant Women and Their Partners for Male HIV Testing

Background: Male partner HIV testing and counseling (HTC) enhances prevention of mother to child HIV transmission (PMTCT), yet male HTC during pregnancy remains low. Identifying male HTC models preferred by pregnant women and their male partners might improve male partner uptake of HIV testing and involvement in maternal and child health. Methodology: In a randomized…

Lay Health Worker Support to Strengthen PMTCT: A Randomised Controlled Trial in South Africa

Background: In South Africa PMTCT services need to be strengthened to eliminate pediatric HIV by 2015. Lay health workers (LHWs) can play an important role in supporting the continuity of care in primary health care services in developing countries. Methodology: This pragmatic cluster randomised controlled trial assessed the effectiveness of LHWs in reducing missed opportunities…

Programmatic Implementation of WHO Option B in Botswana Associated with Increased Projected MTCT

Background: The 2013 WHO guidelines for prevention of mother-to-child transmission (PMTCT) recommend that countries offering antenatal zidovudine (Option A) transition to 3-drug antiretroviral treatment (ART) for all pregnant women, regardless of CD4 count (Option B or B+). In 2009, Botswana became one of the first African countries to transition from WHO Option A to Option…

Early Infection Among Ugandan HIV-Exposed Infants Whose Mothers Received Option B+ vs Option A

Background: Interventions with combination antiretroviral (ARV) treatment during pregnancy and breastfeeding have shown significant progress in prevention of mother to child transmission (PMTCT) of HIV. At Mulago Hospital, Uganda, Option A (antenatal zidovudine plus peripartum single dose nevirapine/zidovudine/3TC tail and infant nevirapine throughout breastfeeding) were used from December 2010 for PMTCT. Option B+ (lifetime ART…

Impact of Option B+ on Uptake Retention and Transmission: A Pre/Post Study in Lilongwe Malawi

Background: In September 2011, Malawi implemented Option B+ (B+), lifelong antiretroviral therapy (ART) for pregnant and breast feeding women. The Tingathe program, started in 2009, two years prior to B+, is a service program utilizing dedicated community health workers (CHWs) as case managers to improve uptake and retention along the PMTCT cascade. The service is…

Epitope Targeting and the Antibody-Dependent Cellular Cytotoxicity Response against HIV-1

Background: Antibody-dependent cellular cytotoxicity (ADCC) has been linked with protection against HIV-1. In the RV144 trial that showed an estimated efficacy of 31%, high levels of ADCC inversely correlate with infection risk. Non-neutralizing epitopes in the C1 region of gp120 have been implicated as potential targets for protective antibody responses elicited by vaccination, although antibody-binding…

B and T Cell Immune Responses to pH1N1 Monovalent Vaccine in HIV+ Pregnant Women in IMPAACT P1086

Background: Pregnant women have a high risk of severe influenza disease that can be mitigated by vaccination. Although HIV+ individuals have modest antibody responses to influenza vaccines, vaccination has been effective against disease, suggesting additional mechanisms of protection. We characterize the B and the T cell responses to pH1N1 vaccine and their determinants in HIV+…